Pfizer said Thursday that it is back in the race to get an effective weight-loss pill to market. The company’s announcement, ...

Pfizer said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

Pfizer, for example ... Baron ranks Structure second behind Lilly in the race to get a weight-loss pill to market. Structure is also a takeover target if GSBR-1290’s trial results continue ...